What Could Come After CAR-T? Cue Is Betting On Selective Biologics

Cue Biopharma Inc., a company developing biologics targeting tumor specific T-cell receptors (TCRs), believes its technology could represent the next wave of cancer immunotherapy – besting even novel chimeric antigen receptor (CAR) T-cell therapies that are yet to reach the market. Still, while Cue is excited about its technology based on promising preclinical data, lots of uncertainties remain around the mechanisms of action for biologic cell therapies.

Cue's hypothesis is based on using biologics to stimulate endogenous TCRs via the peptide major histocompatibility complex (MHC) and TCR interaction – unlike CAR-T therapy this does not involve extracting...